Relative Bioavailability and Bioequivalence of Opicapone
Status:
Completed
Trial end date:
2019-06-09
Target enrollment:
Participant gender:
Summary
the purpose assess the relative bioavailability and bioequivalence of two active
pharmaceutical ingredient (API) sources of opicapone (OPC, Ongentys® and BIA 9-1067)
following single 50 mg dose administration under fasting conditions in healthy volunteers